These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8389017)

  • 1. Aluminium toxicity in dialysis patients: no evidence for a threshold serum aluminium concentration.
    Altmann P
    Nephrol Dial Transplant; 1993; 8 Suppl 1():25-34. PubMed ID: 8389017
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminium studies in dialysis encephalopathy.
    Elliott HL; Macdougall AI
    Proc Eur Dial Transplant Assoc; 1978; 15():157-63. PubMed ID: 740662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients.
    Costantini S; Giordano R; Vernillo I; Piccioni A; Zapponi GA
    Ann Ist Super Sanita; 1989; 25(3):457-61. PubMed ID: 2624356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum aluminium measurements in renal bone disease.
    Lancet; 1983 May; 1(8334):1168-9. PubMed ID: 6133187
    [No Abstract]   [Full Text] [Related]  

  • 5. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum toxicity in children with chronic renal failure.
    Polinsky MS; Gruskin AB
    J Pediatr; 1984 Nov; 105(5):758-61. PubMed ID: 6389807
    [No Abstract]   [Full Text] [Related]  

  • 7. [Adynamic bone disease in kidney failure. Role of aluminum].
    Cohen-Solal ME; Sebert JL; Morinière P; Fournier A
    Rev Rhum Ed Fr; 1993 May; 60(5):361-4. PubMed ID: 8167643
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bone and joint problems in long-term dialysis].
    Brunner FP
    Schweiz Med Wochenschr; 1992 May; 122(19):711-8. PubMed ID: 1594906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminium toxicity during regular haemodialysis.
    Elliott HL; Dryburgh F; Fell GS; Sabet S; Macdougall AI
    Br Med J; 1978 Apr; 1(6120):1101-3. PubMed ID: 638617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients.
    De Broe ME; D'Haese PC; Couttenye MM; Van Landeghem GF; Lamberts LV
    Nephrol Dial Transplant; 1993; 8 Suppl 1():47-50. PubMed ID: 8389021
    [No Abstract]   [Full Text] [Related]  

  • 11. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium.
    Altmann P; Plowman D; Marsh F; Cunningham J
    Lancet; 1988 May; 1(8593):1012-5. PubMed ID: 2896867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in aluminum toxicology.
    Monteagudo FS; Cassidy MJ; Folb PI
    Med Toxicol Adverse Drug Exp; 1989; 4(1):1-16. PubMed ID: 2651849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and therapeutic approaches to aluminium overload in dialysed patients--representative study by questionnaire in West German dialysis units in 1989-1990.
    Hümpfner A; Hummel S; Schulz W
    Nephrol Dial Transplant; 1993; 8 Suppl 1():51-4. PubMed ID: 8389023
    [No Abstract]   [Full Text] [Related]  

  • 16. Red blood cells indices and aluminium toxicity in haemodialysis patients.
    Tielemans C; Kalima L; Collart F; Wens R; Smeyers-Verbeke J; Verbeelen D; Dratwa M
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():395-8. PubMed ID: 3991530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption.
    Heaf JG; Nielsen LP
    Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum aluminium level in the veneto chronic haemodialysis population: cross-sectional study on 1,026 patients.
    Piccoli A; Andriani M; Mattiello G; Nordio M; Modena F; Dalla Rosa C
    Nephron; 1989; 51(4):482-90. PubMed ID: 2787000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
    Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
    Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.